Goldman Sachs Ups Edwards Lifesciences (EW) to Buy, On Product Cycle and Possible Take-Out; NUVA Downgraded
More News related to EW
- Morgan Joseph Initiates Coverage on Edwards Lifesciences (EW) with a Hold; High-Quality Mid-Cap Growth Name
- Edwards Lifesciences Honors Dr. William Ganz' Contributions to Patient Care
- The Edwards Lifesciences Fund to Grant $4.6 Million to Nonprofit Organizations in 2009
- First Transcatheter Valve Cases in Japan Performed With Edwards SAPIEN Valve
- Edwards Lifesciences to Present at the Credit Suisse Annual Healthcare Conference
More News related to NUVA
- NuVasive (NUVA) Appoints Lambert to EVP and CFO; Makes Other Management Changes
- NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
- NuVasive to Host Investor Luncheon on November 11, 2009
- Osiris Therapeutics (OSIR) Achieves $15M Milestone Payment Related to Osteocel Business Sale
- Osiris Therapeutics Achieves $15 Million Milestone Payment
Goldman Sachs upgrades Edwards Lifesciences Corp. (NYSE: EW) from Neutral to Buy and raised their price target from $79 to $95, representing 25% upside. The firm said, "Edwards is the only company across our universe that has a new product cycle, which will drive future margin expansion." Goldman also said EW is the most likely take-out candidate in the group.
In the same report, Goldman downgraded NuVasive (Nasdaq: NUVA) from Buy to Neutral and lowered their price target form $49 to $45, saying they no longer see material upside to consensus estimates. Goldman said the core business will require more SG&A to drive top-line growth.
Real-Time Market Moving News - Two Weeks Free http://www.streetinsider.com/premium_content.php
Related Categories
DowngradesRumors
Trader Talk
Upgrades
Stocks Mentioned
+0.12
-3.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
